doi: 10.1056/NEJMhpr0807774.
Epub 2009 Jan 27.
Limits on Medicare's ability to control rising spending on cancer drugs
Affiliations
- PMID: 19176475
- DOI: 10.1056/NEJMhpr0807774
Item in Clipboard
Limits on Medicare's ability to control rising spending on cancer drugs
N Engl J Med.
.
Erratum in
- N Engl J Med. 2009 Feb 26;360(9):944
No abstract available
Similar articles
-
Drug-altered states. As pharmaceutical spending continues to soar, state legislatures are taking bold steps to rein in their costs.Mod Healthc. 2002 Apr 29;32(17):28-31. Mod Healthc. 2002. PMID: 12024771 No abstract available.
-
Medicare cost containment strategy targets several oncology drugs.J Natl Cancer Inst. 2004 Sep 1;96(17):1268-70. doi: 10.1093/jnci/96.17.1268. J Natl Cancer Inst. 2004. PMID: 15339960 No abstract available.
-
Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model.JAMA Oncol. 2016 Sep 1;2(9):1125-6. doi: 10.1001/jamaoncol.2016.2037. JAMA Oncol. 2016. PMID: 27388928 No abstract available.
-
Reimbursement and patient assistance programs for oral chemotherapy agents.Clin J Oncol Nurs. 2003 Nov-Dec;7(6 Suppl):31-6. doi: 10.1188/03.CJON.S6.31-36. Clin J Oncol Nurs. 2003. PMID: 14705498 Review.
-
The drug budget silo mentality in Europe: an overview.Value Health. 2003 Jul-Aug;6 Suppl 1:S1-9. doi: 10.1046/j.1524-4733.6.s1.1.x. Value Health. 2003. PMID: 12846921 Review. No abstract available.
Cited by
-
Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.Breast Cancer. 2024 Nov;31(6):1144-1155. doi: 10.1007/s12282-024-01634-x. Epub 2024 Sep 25. Breast Cancer. 2024. PMID: 39320645 Free PMC article.
-
Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers.J Oncol Pract. 2012 May;8(3 Suppl):e38s-43s. doi: 10.1200/JOP.2012.000564. J Oncol Pract. 2012. PMID: 22942833 Free PMC article.
-
Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.Pharmacoeconomics. 2018 Dec;36(12):1395-1405. doi: 10.1007/s40273-018-0696-4. Pharmacoeconomics. 2018. PMID: 30062518
-
Current and Future Oncology Management in the United States.J Manag Care Spec Pharm. 2019 Feb;25(2):272-281. doi: 10.18553/jmcp.2019.25.2.272. J Manag Care Spec Pharm. 2019. PMID: 30698085 Free PMC article.
-
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer.J Oncol Pract. 2011 May;7(3 Suppl):e16s-24s. doi: 10.1200/JOP.2011.000294. J Oncol Pract. 2011. PMID: 21886506 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
